Target intelligence / Profile preview

Elongation factor Ts, mitochondrial (TSFM)

Target
TSFM
Molecular classification
Enzyme, Mitochondrial translation elongation factor, Other
01

Overview

Elongation factor Ts, mitochondrial (TSFM) is a nuclear-encoded mitochondrial enzyme required for the elongation phase of protein translation in mitochondria. It acts as a guanine nucleotide exchange factor for elongation factor Tu (EF-Tu), facilitating the recycling of GDP for GTP during translation. TSFM remains transiently associated with the aminoacyl-tRNA.EF-Tu.GTP complex, ensuring efficient peptide elongation on the mitochondrial ribosome. Mutations in TSFM cause rare but severe early-onset mitochondrial disorders, including combined oxidative phosphorylation deficiency, mitochondrial encephalopathies, and cardiomyopathies. There are several splice isoforms, but all share the catalytically important N-terminal region. Pathogenic mutations destabilize the EF-Ts/EF-Tu complex, impairing mitochondrial translation and causing tissue-specific disease phenotypes, predominantly in the heart and nervous system. No approved drugs target TSFM, and therapeutic intervention is highly challenging due to its essential role in mitochondrial protein synthesis and cell viability.

Other names
Ts translation elongation factor, mitochondrialEF-TsEF-TsMtEF-TsmtEF-TSEFTSEFTSMTTs translation elongation factorEFTS ProteinP43897 (UniProt)
02

Mechanism of action

For interacting compounds such as kirromycin, the mechanism involves perturbing the conformational relationship between EF-Tu and EF-Ts, affecting nucleotide exchange. In general, TSFM activity is essential for mitochondrial protein translation, so any inhibitor would block mitochondrial protein synthesis by preventing GDP/GTP exchange on EF-Tu.

03

Biological functions

Exchange of guanine nucleotidesFacilitation of protein synthesisRNA binding
04

Disease associations

Mitochondrial diseaseCardiomyopathyEncephalopathy, optic/peripheral neuropathy, and ataxia
05

Safety considerations

Therapeutic inhibition of TSFM would likely cause severe mitochondrial dysfunction, affecting high-energy tissues (heart, brain, muscle).No known safe pharmacological inhibition exists. Mutations lead to severe disease phenotypes, indicating essential function.
06

Interacting drugs

kirromycin
07

Biomarkers

TSFM mutation statusReduced EF-Ts and EF-Tu protein levels

Beyond the preview

Go deeper on Elongation factor Ts, mitochondrial (TSFM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elongation factor Ts, mitochondrial (TSFM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call